Evidence map›Paper›PMID 35299992›Full record

ArticleClinicoEconomics and outcomes research : CEOR2022

Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy.

Luca Degli Esposti, Chiara Veronesi, Domenica Daniela Ancona, Margherita Andretta, Fausto Bartolini, Alberto Drei, Alessandro Lupi, Stefano Palcic, Davide Re, Francesca Vittoria Rizzi and 2 more

Open access · goldAbstract read
In one paragraph

Article in ClinicoEconomics and outcomes research : CEOR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Luca Degli EspostiCliCon S.r.l. Health, Economics & Outcomes Research, Bologna, Italy.ORCID 0000-0002-7020-6659
Chiara VeronesiCliCon S.r.l. Health, Economics & Outcomes Research, Bologna, Italy.
Domenica Daniela AnconaDipartimento Farmaceutico, ASL BAT, Trani, Italy.
Margherita AndrettaUOC Assistenza Farmaceutica Territoriale, Azienda ULSS 8 Berica, Vicenza, Italy.
Fausto BartoliniDipartimento Farmaceutico, Umbria 2, Terni, 05100, Italy.
Alberto DreiDeloitte, Milano, Italy.
Alessandro LupiCardiology Unit, ASL VCO, Omegna, Italy.ORCID 0000-0003-3644-0449
Stefano PalcicFarmaceutica Territoriale, Azienda Sanitaria Universitaria Integrata Giuliano-Isontina, Trieste, Italy.
Davide ReUOC Assistenza Farmaceutica Territoriale, ASL Teramo, Teramo, Italy.
Francesca Vittoria RizziDipartimento Farmaceutico, ASL BAT, Trani, Italy.
Elisa GiacominiCliCon S.r.l. Health, Economics & Outcomes Research, Bologna, Italy.
Valentina PerroneCliCon S.r.l. Health, Economics & Outcomes Research, Bologna, Italy.
ASM Terni (Italy) · ITAzienda Sanitaria Universitaria Integrata di Trieste · ITUniversity of Teramo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This real-world study investigates the direct healthcare costs from the perspective of the Italian Healthcare National Service of experienced statin users according to their level of adherence to therapy and to their cardiovascular (CV) profile in Italian settings of outpatients clinical practice. Patients and Methods: A retrospective observational analysis was performed based on administrative databases covering approximately 6 million health-assisted individuals. Adult patients with statins prescription between January 2014 and December 2016 were screened, and first prescription within this period was the index date. Follow-up lasted 1 year after index date. Only patients receiving statins prior index date (experienced statin users) were included and distributed in clusters based on their CV profile. Adherence was calculated during follow-up as proportion of days covered (PDC) and classified in low adherence (PDC<40%), partial adherence (PDC=40-79%) and adherence (PDC≥80%). Mean direct healthcare costs of drugs, hospitalizations, and outpatient services were evaluated during follow-up. Results: A total of 436,623 experienced statin users were included and distributed as follows: 5.5% in the previous CV events, 22.6% in diabetes, 55.7% in CV treatments and 16.2% in the no comorbidity cluster. Total mean annual cost/patient decreased from low adherent to adherent patients from €4826 to €3497 in previous CV events, from €2815 to €2360 in diabetes cluster, from €2077 to €1863 for patients with CV treatments. Same trend was reported for the cost item related to hospitalizations, which was the major determinant of the total costs. In previous CV event cluster, adherence was associated to a saving of €879 on total costs. Conclusion: The study highlighted a decrease in overall mean costs as adherence levels increase, particularly for patients with previous CV events, showing how improving adherence could be associated to cost savings and suggesting suited strategy based on CV profile should be undertaken for adherence optimization.

Indexed as

direct costslipid-lowering drugsmedication adherencereal-life

Identifiers

PMID35299992
PMCPMC8922236
OpenAlexW4220702972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.